Fabry disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• SGLT2 0
• GIP 0
• VEGF 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 190 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico

  NCT07494058· Takeda· Updated 11 Sept 2026

  “Study was terminated early due to structural and methodological limitations identified in the primary data sources impacting validity, completeness, and clinical robustness of the expected results”Registry text, quoted unchanged. Source

• Terminated

  Cardiovasculorenal Phenotyping in Fabry Disease Through Noninvasive Testing

  NCT05699265· Children's Hospital Medical Center, Cincinnati· Updated 19 Jun 2025

  “The sponsor withdrew funding since there was no progress with this study for a significant amount of time.”Registry text, quoted unchanged. Source

• Terminated

  Screening for Fabry Disease in Renal Transplantation

  NCT03886714· University Hospital, Montpellier· Updated 16 May 2025

  “Low recreuitement numbers and end of grant.”Registry text, quoted unchanged. Source

• Terminated

  Study of the Effects of Fabrazyme Treatment on Lactation and Infants

  NCT00230607· Genzyme, a Sanofi Company· Updated 10 Apr 2024

  “Per FDA decision, the 2003 Post Marketing commitment has been fulfilled.”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation of Phenotypic Variability in Fabry Disease

  NCT03145779· Boston Children's Hospital· Updated 3 Dec 2020

  “Funding”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

  NCT05206773· Sanofi· Source

• Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan

  NCT06052800· Sanofi· Source

• A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico

  NCT07494058· Takeda· Source

• A Study of Replagal in Children and Adults With Fabry Disease in India

  NCT05067868· Shire· Source

• A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

  NCT05280548· Sanofi· Source

• Early Detection of Fabry Disease

  NCT05106764· Takeda· Source

• A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease

  NCT07187440· Takeda· Source

• A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

  NCT06019728· Sanofi· Source

• A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

  NCT04974749· Takeda· Source

• Study of the Effects of Fabrazyme Treatment on Lactation and Infants

  NCT00230607· Genzyme, a Sanofi Company· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Organoids 1
• Exome Sequencing 1
• Proteomics 3
• Flow Cytometry 1
• Magnetic Resonance Imaging 5
• Deep Learning 1
• Cohort Studies 7
• Genome-Wide Association Study 2

• Epigenetic aging and autosomal methylation remodeling in Anderson-Fabry disease.

  Exp Gerontol, Sept 2026

• Genetic Modifiers of Cardiac Remodeling Severity in IVS4+919G>A-Associated Fabry Cardiomyopathy.

  Int J Mol Sci, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.